Why the study?
Does PGE2 improve platelet aggregation and serotonin release in patients with thrombasthenia?
Does PGE2 improve platelet aggregation and serotonin release in patients with thrombasthenia?
PGE2 does not enhance platelet aggregation in thrombasthenic platelets and is therefore not considered useful for treating bleeding in these patients.
Answers are grounded in this paper and cite their sources.
PGE2 does not augment aggregation in thrombasthenia; case report leaves open any therapeutic role in bleeding management.
Four patients with thrombasthenia have been investigated. All patients showed impaired platelet aggregation by ADP, epinephrine and collagen, decreased platelet adhesiveness, and deficient clot retraction. In all the patients, however, platelet serotonin release induced by collagen was normal. In addition, arachidonate caused an induction of serotonin release in thrombasthenic platelets, although the degree of the release was markedly diminished in 2 patients. Platelets of these patients contained normal amounts of ADP, serotonin and c-AMP. PGE2 failed to augment platelet aggregation by ADP and collagen in these patients. In contrast, PGE2 slightly enhanced platelet serotonin release induced by collagen in 2 patients, but had no effect in others. Thus PGE2 is not considered to be useful for the treatment of bleeding in patients with thrombasthenia.
No takes yet. Share an insight, caveat, or question.
Ryo et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: